Catalent to buy Paragon Bioservices for $1.2 bln – WSJ

(Reuters) – Drug developer Catalent Inc has agreed to buy privately held, gene-therapy focused Paragon Bioservices Inc for $1.2 billion (917.64 million pounds), the Wall Street Journal reported on Sunday, citing people familiar with the matter.

An all-cash deal between the companies is expected to be announced on Monday morning and would help Catalent expand its capabilities to develop specialized and costly gene therapy treatments, the Journal said.

Catalent and Paragon did not immediately respond to requests for comment on Sunday.

Drug companies have been moving aggressively into gene therapy, where treatments for rare, inherited diseases command some of the highest prices in medicine.

Paragon, backed by private-equity firms Camden Partners and NewSpring Capital, focuses on developing gene therapy, next-generation vaccines, and other complex biopharmaceuticals for its clients.

The Baltimore, Maryland-based company is expected to record more than $200 million in revenue this year, the Journal said.

Gene therapies use specially engineered viruses, or viral vectors, to deliver genetic material into defective cells, in hopes of improving or potentially even curing an inherited condition.

Somerset, New Jersey-based Catalent also develops drugs for other companies and does business in Asia, Europe, and North and South Americas.

Its biologics and specialty drug business generated about $602 million in revenue in the 2018 financial year.

If confirmed, the deal would follow other multi-billion-dollar deals involving gene therapy companies.

Swiss drugmaker Roche agreed to buy U.S.-based gene therapy specialist Spark Therapeutics Inc for $4.3 billion in February, while Novartis purchased U.S.-based Avexis for $8.7 billion last year, also to gain a platform of gene therapies.

Reporting by Ismail Shakil in Bengaluru; Editing by Chris Reese

Source

more recommended stories

  • WHO likely to declare Ebola an international emergency: experts

    GENEVA (Reuters) – The World Health.

  • U.S. drugmakers file lawsuit against requiring drug prices in TV ads

    FILE PHOTO: Used blister packets that.

  • Death toll from UK hospital listeria outbreak rises to five

    LONDON (Reuters) – The number of.

  • Female soldiers wanting to suppress periods face barriers

    (Reuters Health) – Military women wanting.

  • Chronic depression after heart attack tied to increased risk of death

    (Reuters Health) – Heart attack survivors.

  • North Korea steps up measures to prevent spread of African swine fever

    SEOUL (Reuters) – North Korea has.

  • Missouri’s only abortion clinic to stay open after injunction issued

    (Reuters) – The only abortion clinic.

  • China to tighten rules on foreigners using genetic material

    FILE PHOTO: A researcher inserts a.

  • Experimental drug delays type 1 diabetes onset in mid-stage trial

    (Reuters Health) – In people at.

  • Abbott device helps in cutting blood sugar in type 2 diabetics: study

    (Reuters) – Insulin-dependent patients with type.

  • USDA investigates unapproved GMO wheat found in Washington state

    CHICAGO (Reuters) – The U.S. Department.

  • As pressure for Afghan peace grows, drug threat remains

    KANDAHAR, Afghanistan (Reuters) – Mohammad Ahmadi,.

  • One in four Ebola cases undetected in Congo: WHO

    GENEVA (Reuters) – Roughly a quarter.

  • U.S. health agency cancels research contract involving use of fetal tissue

    (Reuters) – The Department of Health.

  • Many U.S. kids still eating laundry pods

    Many American children are still being.

  • Nipah virus resurfaces in India’s Kerala after killing 17 last year

    NEW DELHI (Reuters) – The deadly.

  • Therapy in the office: banks take mental health fight in-house

    LONDON (Reuters) – In ‘Billions’, a.

  • Lynparza stalls pancreatic cancer in patients with BRCA mutations: study

    CHICAGO (Reuters) – AstraZeneca and Merck.

  • Novartis hopes Kisqali data will help narrow gap to blockbuster rival

    ZURICH (Reuters) – Novartis has released.

  • Missouri abortion clinic to stay open for now after court order

    ST. LOUIS (Reuters) – Missouri’s only.

  • South Korea braces for African swine fever outbreak after North Korea case

    SEOUL (Reuters) – South Korea readied.

  • Louisiana governor to sign ‘heartbeat’ ban, latest move to curb U.S. abortion rights

    (Reuters) – Louisiana’s Democratic governor said.

  • UK institute, Belgian firm team up for African swine fever treatment

    LONDON (Reuters) – Britain’s Pirbright Institute.

  • Overweight teen boys have higher risk of heart muscle damage as adults

    (Reuters Health) – Men who were.

  • British Columbia to be first Canadian province to switch patients to biosimilars

    TORONTO/MONTREAL (Reuters) – The Canadian province.

  • Vietnam swine fever cull surges, 1.7 million pigs dead

    FILE PHOTO: Pork is displayed for.

  • Support for abortion rights grows as some U.S. states curb access – Reuters/Ipsos poll

    NEW YORK (Reuters) – Americans have.

  • Groups sue over Alabama abortion law; judge blocks Mississippi ban

    (Reuters) – The American Civil Liberties.

  • Novartis $2 million gene therapy for rare disorder is world’s most expensive drug

    ZURICH/NEW YORK – Swiss drugmaker Novartis.

  • Exclusive: JPMorgan cuts ties with OxyContin maker Purdue Pharma – sources

    (Reuters) – JPMorgan Chase & Co.

  • Novartis has 25 blockbusters in the pipeline: CEO

    FILE PHOTO: Logo of Swiss drugmaker.

  • Senator Gillibrand wants insurance to pay for fertility treatments

    WASHINGTON (Reuters) – U.S. Democratic presidential.